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Background: A more specific and early diagnostics for prostate cancer (PCa) is highly desirable. In this study, being
inflammation the focus of our effort, serum protein profiles were analyzed in order to investigate if this parameter
could interfere with the search of discriminating proteins between PCa and benign prostatic hyperplasia (BPH).
Methods: Patients with clinical suspect of PCa and candidates for trans-rectal ultrasound guided prostate biopsy
(TRUS) were enrolled. Histological specimens were examined in order to grade and classify the tumor, identify BPH
and detect inflammation. Surface Enhanced Laser Desorption/Ionization-Time of Flight-Mass Spectrometry (SELDI-
ToF-MS) and two-dimensional gel electrophoresis (2-DE) coupled with Liquid Chromatography-MS/MS (LC-MS/MS)
were used to analyze immuno-depleted serum samples from patients with PCa and BPH.
Results: The comparison between PCa (with and without inflammation) and BPH (with and without inflammation)
serum samples by SELDI-ToF-MS analysis did not show differences in protein expression, while changes were only
observed when the concomitant presence of inflammation was taken into consideration. In fact, when samples with
histological sign of inflammation were excluded, 20 significantly different protein peaks were detected. Subsequent
comparisons (PCa with inflammation vs PCa without inflammation, and BPH with inflammation vs BPH without
inflammation) showed that 16 proteins appeared to be modified in the presence of inflammation, while 4 protein
peaks were not modified. With 2-DE analysis, comparing PCa without inflammation vs PCa with inflammation, and
BPH without inflammation vs the same condition in the presence of inflammation, were identified 29 and 25
differentially expressed protein spots, respectively. Excluding samples with inflammation the comparison between
PCa vs BPH showed 9 unique PCa proteins, 4 of which overlapped with those previously identified in the presence
of inflammation, while other 2 were new proteins, not identified in our previous comparisons.
Conclusions: The present study indicates that inflammation might be a confounding parameter during the
proteomic research of candidate biomarkers of PCa. These results indicate that some possible biomarker-candidate
proteins are strongly influenced by the presence of inflammation, hence only a well-selected protein pattern should
be considered for potential marker of PCa.
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Despite the improvements in clinical and surgical prac-
tice, prostate cancer (PCa) remains one of the most
widespread cancers in males, with an unchanged mortal-
ity rate [1-4].
The serum marker currently used for the diagnosis of
PCa is the prostate-specific antigen (PSA), which is not
particularly reliable, having a predictive value estimated
at 25%-35% in the range of 2.6 – 10 ng/mL [2]. Further-
more, benign conditions such as prostatitis and benign
prostatic hyperplasia (BPH) can lead to an increase in
PSA levels causing false positive [5,6]. With the aim of
improving accuracy in the detection, monitoring and
distinction between benign conditions and PCa, it is im-
perative to identify new and reliable molecular targets.
In recent years, proteomic techniques have achieved a
rapid evolution, due to innovative experimental ap-
proaches and improvements in sensitivity, resolution
and accuracy of the mass analysers. Several proteomic
studies have been carried out on serum [7,8], urine [9],
biopsy tissue [10] and cell lines [11,12], with the purpose
of identifying promising targets for the early detection of
PCa. Unfortunately, the majority of the candidate bio-
markers are still awaiting validation [13,14]. Other stud-
ies have been performed in the attempt to discriminate
PCa from BPH. Adam and co-workers used the protein
profiling technology approach coupled with an artificial
intelligence data analysis algorithm to distinguish PCa
from non-cancer forms [15]. In another study, Ornstein
et al. reported serum proteomic patterns obtained by
Surface Enhanced Laser Desorption/Ionization-Time of
Flight-Mass Spectrometry (SELDI-ToF-MS) analysis to
discriminate PCa from BPH when PSA level is between
2.5 and 15 ng/mL, with the aim to decrease unnecessary
prostate biopsies [16]. More recently, Ummanni et al.
examined biopsy samples from BPH and PCa patients
using two-dimensional gel electrophoresis (2-DE) followed
by Matrix Assisted Laser Desorption/Ionization-Time of
Flight-Mass Spectrometry analysis (MALDI-ToF-MS), to
identify potential biomarkers that might differentiate the
two clinical events [17].
In this study, in order to identify distinctive protein
profiles able to unquestionably discriminate patients
with a benign prostate condition from those with a ma-
lignant situation, the serum protein expression of PCa
and BPH was investigated by proteomics.
Differently from previous publications, the benign states
were considered vs the pathological ones focusing on the
co-existence of inflammation, since emergent research
underline a tight link between chronic inflammation and
endothelial activation in both PCa and BPH [18-20].
Cancer and inflammation are closely linked, so much
that cancer patients show both local and systemic
changes in inflammatory parameters. In some cancertypes, inflammatory conditions are present before a ma-
lignant change occurs; otherwise, in different type of
cancer, an oncogenic alteration generates an inflamma-
tory microenvironment that induces the development of
tumors [21]. In PCa and BPH conditions, inflammation
is frequently evident in prostate biopsies, radical prosta-
tectomy specimens and tissue resected for the treatment
of BPH. For this reason, the inflammatory injury, and
consequently its chemical mediators and protein prod-
ucts, should be taken into account in proteomic studies
aimed to identify PCa biomarkers.
In our study, serum samples were depleted of high-
abundant proteins by immuno-chromatography and the
depleted samples were analysed by SELDI-ToF-MS. This
is a sensitive proteomic technique that analyses proteins
on large scale in a relatively short time and therefore it
is of help for the preliminary screening of complex sam-
ples and for biomarkers search. Subsequently, samples
were analysed by 2-DE coupled with LC-MS/MS, in
order to precisely identify relevant proteins.
Results and discussion
Cancer survival rates depend on the early detection of
the disease: currently, PCa diagnosis is performed using
digital rectal exploration (DRE), trans-rectal ultrasound
guided prostate biopsy (TRUS), and by the measurement
of serum PSA levels. PSA is a sensitive marker for the
detection of PCa, however it is not cancer-specific; ele-
vated serum PSA levels are also observed in benign en-
largements of the prostate, such as BPH or prostatitis,
and after biopsy [22].
In this study, the serum proteins associated with PCa
were compared to BPH, in order to identify distinctive
protein profiles able to unquestionably discriminate pa-
tients with a malignant situation from those with a be-
nign prostate condition. The study was conducted taking
into consideration that inflammation is an intrinsic com-
ponent of the cancer and BPH.
Because high-abundance proteins present in serum
can interfere with resolution and sensitivity of proteo-
mics, by masking low concentration proteins, serum
samples were depleted by immunoaffinity chromatog-
raphy. This procedure reduces the complexity of serum
samples and enriches low-abundance proteins; moreover,
it offers the lowest co-depletion of untargeted proteins,
proving to be the most advantageous depletion approach
for serum preparation prior to proteomic studies [23].
The analysis was first carried out by SELDI-ToF-MS
using the H50 ProteinChip surface, irrespective of the
presence of inflammation. Under this condition, no dif-
ferential expression of protein peaks was evident be-
tween PCa samples (n = 31) and BPH (n = 30).
Since inflammation is often associated to both PCa
and BPH, its influence on the serum protein profile was
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logical signs of inflammation, protein spectra from pa-
tients with PCa were compared to BPH (10 and 11
patients respectively).
This comparison showed evident differences in the
protein profile, leading to the identification of 20 differ-
entially expressed protein peaks; in particular, 5 peaks
resulted increased (m/z 2325, 2348, 2373, 2581, 3104)
and 15 peaks decreased (m/z 6624, 6837, 9352, 9922,
13775, 14031, 14106, 14473, 14763, 22668, 28052,
28242, 29018, 45350, 56390) in PCa compared to BPH
(Table 1).
The specific protein expression of PCa with inflamma-
tion vs the same condition in absence of inflammation
were subsequently compared. In this case, 9 protein
peaks differentially expressed were detected: 4 peaks
were increased (m/z 9352, 9922, 21739, 29018) and 5
peaks were decreased (m/z 2325, 2348, 3104, 3215,
17471) in the presence of inflammation. Notably, 6 pro-
tein peaks coincided with 6 of the 20 peaks differentiallyTable 1 Differentially expressed peaks in PCa vs BPH
excluding samples with inflammation detected by
SELDI-ToF-MS
Peak m/z PCa intensity
peak
BPH intensity
peak
t-test
p-value
Increased
1 2325 4.29 1.32 0.002
2 2348 3.97 1.18 0.006
3 2373 3.27 1.10 0.005
4 2581 1.34 0.33 0.002
5 3104 2.19 0.88 0.007
Decreased
1 6624 17.63 24.54 0.037
2 6837 2.37 3.19 0.010
3 9352 1.84 2.38 0.033
4 9922 0.44 0.66 0.048
5 13775 1.21 1.67 0.049
6 14031 2.76 4.98 0.001
7 14106 1.67 2.66 0.005
8 14473 0.55 0.85 0.0003
9 14763 0.57 0.76 0.002
10 22668 0.06 0.10 0.003
11 28052 2.05 3.90 0.003
12 28242 1.42 2.33 0.011
13 29018 0.48 0.93 0.003
14 45350 0.78 1.23 0.002
15 56390 0.84 1.32 0.026
Statistical analysis was performed by Student’s t test. The table shows the
p-values statistically significant (p ≤ 0.05).expressed in the comparison between PCa and BPH in
the absence of inflammation (Table 2, peaks in italic).
The same approach was applied to BPH and 15 peaks
were found to be differentially expressed when BPH
samples with and without inflammation were compared:
5 increased (m/z 2325, 2348, 2373, 2581, 3104) and 10
decreased (m/z 6433, 6624, 6837, 9352, 14031, 14106,
14473, 22668, 28052, 45350) in the presence of inflam-
mation. Particularly, all peaks differently expressed, ex-
cept one (m/z 6433), overlapped with peaks found also
in the comparison between PCa and BPH in the absence
of inflammation (Table 3, peaks in square brackets).
In summary, SELDI-ToF-MS analysis demonstrated
that, in the absence of inflammation, 20 different protein
peaks are expressed in PCa in respect to BPH. Of these,
only 4 peaks, highlighted in Table 4 (in bold) and shown
in Figure 1, could potentially differentiate PCa from
BPH, since their expression is not altered by the pres-
ence of inflammation. The remaining 16 peaks (also
found differentially expressed in presence of inflamma-
tion) seem to be strongly related to inflammation, hence
they can not be used as markers of PCa (Table 4). The
inflammatory process therefore appears to be a limiting
factor in the search of biomarkers able to discriminate
PCa from BPH and it has not be underrated, since it
represents a key mechanism in the development and
progression of both diseases [24]. Inflammation is often
observed in tumors, with immune cell infiltration and ac-
tivated stroma. For this reason, cancer patients frequently
present changes in various systemic parameters, com-
prising alterations in the level of serum inflammatoryTable 2 Differentially expressed peaks in PCa with
inflammation vs PCa without inflammation detected by
SELDI-ToF-MS
Peak m/z PCa with
inflammation
intensity peak
PCa without
inflammation
intensity peak
t-test
p-value
Increased
1 9352 2.26 1.84 0.050
2 9922 0.64 0.45 0.040
3 21739 0.08 0.05 0.019
4 29018 0.75 0.49 0.043
Decreased
1 2325 2.51 4.29 0.025
2 2348 2.28 3.97 0.044
3 3104 1.24 2.19 0.025
4 3215 1.49 1.96 0.024
5 17471 2.67 3.25 0.047
Statistical analysis was performed by Student’s t test. The table shows the
p-values statistically significant (p ≤ 0.05). Protein peaks in italic: protein peaks
found also in the comparison between PCa and BPH excluding samples with
inflammation (Table 1).
Table 3 Differentially expressed peaks in BPH with
inflammation vs BPH without inflammation detected by
SELDI-ToF-MS
Peak m/z BPH with
inflammation
intensity peak
BPH without
inflammation
intensity peak
t-test
p-value
Increased
1 [2325] 3.28 1.32 0.016
2 [2348] 3.34 1.84 0.013
3 [2373] 2.93 1.10 0.009
4 [2581] 1.06 0.33 0.007
5 [3104] 1.74 0.88 0.037
Decreased
1 6433 9.65 12.61 0.009
2 [6624] 18.39 24.54 0.017
3 [6837] 2.51 3.19 0.018
4 [9352] 1.92 2.38 0.037
5 [14031] 3.49 4.98 0.012
6 [14106] 2.00 2.66 0.036
7 [14473] 0.68 0.85 0.033
8 [22668] 0.07 0.10 0.011
9 [28052] 2.82 3.90 0.033
10 [45350] 0.94 1.23 0.037
Statistical analysis performed by Student’s t test. The table shows the p-values
statistically significant (p ≤ 0.05). Protein peaks in square: protein peaks found
also in the comparison between PCa and BPH excluding samples with
inflammation (Table 1).
Table 4 Comparison of peaks intensities differentially
expressed in PCa vs BPH detected by SELDI-ToF-MS
Peak m/z Intensity peak
PCA (n = 31) BPH (n = 30)
Inflammation Inflammation
Absent
(n = 10)
Present
(n = 21)
Absent
(n = 11)
Present
(n = 19)
1 2325 4.30 2.51 1.32 3.28
2 2348 3.97 2.28 1.84 3.34
3 2373 3.28 1.95* 1.10 2.93
4 2581 1.34 0.85* 0.33 1.06
5 3104 2.20 1.24 0.88 1.74
6 6624 17.63 18.93* 24.54 18.39
7 6837 2.37 2.54* 3.19 2.51
8 9352 1.84 2.26 2.38 1.92
9 9922 0.44 0.64 0.66 0.52*
10 13775 1.21 1.58* 1.67 1.57*
11 14031 2.76 3.74* 4.98 3.49
12 14106 1.67 2.14* 2.66 2.00
13 14473 0.55 0.73* 0.85 0.68
14 14763 0.57 0.66* 0.76 0.71*
15 22668 0.06 0.08* 0.10 0.07
16 28052 2.05 3.06* 3.90 2.82
17 28242 1.42 1.88* 2.33 1.81*
18 29018 0.48 0.75 0.93 0.68*
19 45350 0.78 1.00* 1.23 0.94
20 56390 0.84 1.24* 1.32 1.09*
Protein peaks in bold: protein peaks discriminating PCa from BPH.
*Differences not statistically significant.
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fact, inflammation generates not only cancer-promoting
microenvironment changes, but also systemic alterations
that promote cancer progression [26]. Despite the evi-
dence that inflammation is an intrinsic component of can-
cer, this fundamental aspect is often ignored in biomarker
research studies.
The indications reported above and the preliminary re-
sults obtained in the present study by SELDI-ToF-MS
analysis, suggested that inflammation could be a con-
founding factor in the identification of protein profiles
able to discriminate between PCa and BPH. Afterward,
to verify this supposition, proteomic analysis was per-
formed by 2-DE coupled with MS.
Representative 2-D gels obtained from depleted serum
samples are reported in Figure 2. Inflammation-free PCa
vs PCa with inflammation were first compared (first com-
parison); then, BPH was considered in the absence or
presence of inflammation (second comparison), and finally
the two conditions were compared with the exclusion of
inflammation (third comparison). The differentially ex-
pressed protein spots are marked in the images by alpha-
numeric labels, that correspond to those reported in the
first column of Tables 5, 6 and 7, respectively. The second
column of Tables 5, 6 and 7 refers to the primaryaccession number, derived from the UniProt knowledge
database, the third column provides the complete name of
each identified protein and column 4 reports the theoret-
ical molecular weight (MW). Column 5 shows the highest
ion scores obtained with MASCOT search engine,
expressed as the probability that the observed match be-
tween the experimental data and the database sequence
could be due to a random event. Column 6 indicates the
total number of peptides that matched the identified pro-
teins and the significant matches, while column 7 reports
the total number of sequences and the number of signifi-
cant sequences. Finally, the last column reports the pro-
tein expression change, indicated by arrows.
In the presence of inflammation, the first comparison
showed 29 spots differentially expressed corresponding
to 17 unique proteins (Table 5 and Figure 2B), while the
second comparison showed 25 spots differentially ex-
pressed corresponding to 15 unique proteins (Table 6 and
Figure 2D).
Ten unique proteins, corresponding to 20 and 19 spots
in the first and second comparison respectively, were
Figure 1 Representative spectra obtained by SELDI-ToF-MS analysis concerning the 4 statistically significant peaks detected with H50
ProteinChip Array.
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ence of inflammation (yellow labels in Figure 2B and in
2D, respectively). Seven of these proteins resulted increased
in both conditions: Complement factor B, Prothrombin,
Beta-2-glycoprotein 1, Complement C3 fragment, Zinc-
alpha-2-glycoprotein, Clusterin and Retinol binding pro-
tein. Apolipoprotein CIII appeared decreased in PCa and
increased in BPH, while Inter-alpha-trypsin inhibitor heavy
chain and Haptoglobin resulted increased in PCa and de-
creased in BPH (Tables 5 and 6, proteins name in italic).
When the two conditions were compared in the absence
of inflammation (third comparison), 9 unique proteins dif-
ferentially expressed, corresponding to 16 spots, were
found in PCa (Figure 2A and Table 7). Precisely, 4 resulted
increased: Prothrombin, Complement C4-B, fragments of
Complement C3 and Zinc-alpha-2-glycoprotein; while 5
were decreased: Hemopexin, Antithrombin-III, Pigment
epithelium-derived factor, Haptoglobin and Serum Amyl-
oid A-1 protein.
Serum Amyloid A-1 protein is an acute phase protein
that is synthesized under the regulation of inflammatory
cytokines during both acute and chronic inflammation
[27]. In a recent study reported by Menschikowski et al.,
this protein is considered a circulating biomarker of in-
flammation during BPH development and PCa progres-
sion [28]. In our study, Serum Amyloid A-1 protein was
found decreased in BPH without inflammation (Table 6)in accordance with the literature data, while in PCa pa-
tients this protein did not shown any changes.
As highlighted in Figure 2A (yellow labels) and in
Table 7 (protein names in italic), in third comparison
were found some proteins identified also in PCa and BPH
in the presence of inflammation (probably inflammation-
linked proteins), such as fragments of Complement C3,
Prothrombin, Haptoglobin and Zinc-alpha-2-glycoprotein.
This can be clearly explained since a certain degree of in-
flammation is always present in PCa.
The most interesting result observed in third com-
parison is the detection of 2 proteins, not identified
in the previous comparisons, namely Hemopexin and
Antithrombin-III, (Figure 2A, green labels and Table 7,
protein names in bold).
Hemopexin (or β1B-glycoprotein) is a heme-binding
serum protein with high carbohydrate content and
immunoelectrophoretic identity. The most important
physiological role of Hemopexin is to act as an antioxi-
dant in case of heme overload, rather than to participate
in iron metabolism [29]. In a recent work, Hemopexin
N-glycan profile was indicated to be of diagnostic value
in hepatocellular carcinoma patients [30].
Antithrombin-III is a member of the serpin family and
functions as an inhibitor of thrombin and other enzymes
involved in the clotting cascade; moreover, it has been
demonstrated to possess a potent antiangiogenic activity
Figure 2 Bi-dimensional proteome maps of serum samples from PCa without (A) and with inflammation (B), and BPH in absence (C)
and presence of inflammation (D). Proteins were resolved by IEF over the pH range 4–7, followed by 8-16% gradient gel and visualized by
Silver staining. Significant differentially expressed proteins are marked with alphanumeric labels, corresponding to those listed in Tables 5, 6 and
7. Yellow tags indicate the overlapped proteins detected in presence of inflammation in both PCa (B) and BPH (D) conditions. Some of these
proteins were also revealed in PCa in absence of inflammation (A, third comparison). Additionally, in this latter situation, green labels represent
proteins not previously identified in the first and second comparisons, namely in presence of inflammation.
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expression of Antithrombin in benign and malignant
prostate gland. They found that this protein was widely
expressed in PCa, but was gradually lost in tumors with
high Gleason grade [32]. A decrease in plasma levels of
Antithrombin-III is also reported in patients with colon
and ovarian cancer, especially in presence of metastasis
[33], other than in PCa [34]. In our study, we found a
significantly lower expression of Antithrombin-III in
PCa than the BPH. Hence, the local anti-angiogenic ac-
tivity of Antithrombin-III may be partially lost in ad-
vanced stages of PCa.
The comparison of the protein profile between PCa
and BPH by 2-DE showed several differentially expressed
proteins, the majority of which could be related to the
inflammatory process and not to the pathological condi-
tion. These results confirm those obtained by SELDI-
ToF-MS analysis although it is not possible to perform adirect correspondence between the two techniques be-
cause the analytical conditions are different (pre-analyt-
ical sample treatment, detection of proteins in different
mass range, use of selective chromatographic surface
with the SELDI-ToF-MS technology).Conclusions
This paper emphasizes the importance of considering in-
flammation in endeavours aimed to the discovery of spe-
cific markers capable to differentiate PCa from BPH.
Using two different proteomic techniques we have
clearly demonstrated that, in the presence of inflamma-
tion, the majority of the differentially expressed protein
peaks detected by SELDI-ToF-MS and of protein spots
revealed by 2-DE analysis can’t be considered discrimin-
ating markers of PCa. Therefore, the inflammatory
process masks the detection of some proteins, which
Table 5 Differentially expressed proteins in PCa without inflammation vs PCa with inflammation (UniProtKB database)
Spot n°. Acc. n°. Protein full name Mass (Da) Score N° matchs/signif. matchs N° seq./signif. seq. Expression
change
B1 P00751 Complement factor B 86847 445 212/60 33/19 ↑
B2 P00734 Prothrombin 71475 455 75/39 15/7 ↑
B3 P02749 Beta-2-glycoprotein 1 39584 458 81/42 17/8 ↑
B4 P02749 Beta-2-glycoprotein 1 39584 288 69/32 14/12 ↑
B5 P02749 Beta-2-glycoprotein 1 39584 122 55/17 11/8 ↑
B6 P02749 Beta-2-glycoprotein 1 39584 35 28/4 6/3 ↑
B7 P36955 Pigment epithelium-derived factor 46454 142 46/13 11/8 ↑
B8 P36955 Pigment epithelium-derived factor 46454 65 42/12 13/5 ↑
B9 P36955 Pigment epithelium-derived factor 46454 51 35/8 13/7 ↑
B10 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 103521 375 152/47 30/13 ↑
B11 P00738 Haptoglobin 45861 110 83/21 17/7 ↑
B12 P00738 Haptoglobin 45861 236 99/28 18/8 ↑
B13 P00738 Haptoglobin 45861 138 97/16 18/6 ↑
B14 P25311 Zinc-alpha-2-glycoprotein 34465 104 24/9 10/4 ↑
B15 P01024 Complement C3 (fragment) 188569 104 49/8 21/4 ↑
B16 P01024 Complement C3 (fragment) 188569 2354 365/180 38/27 ↑
B17 P10909 Clusterin 53031 241 57/16 10/4 ↑
B18 P10909 Clusterin 53031 138 31/12 7/3 ↑
B19 P10909 Clusterin 53031 202 55/22 11/7 ↑
B20 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 103521 41 13/3 2/2 ↑
B21 P02649 Apolipoprotein E 36246 398 125/43 27/13 ↑
B22 P02766 Transthyretin 15991 1086 165/71 16/11 ↑
B23 P02743 Serum amyloid P-component 25485 304 43/20 8/6 ↑
B24 O75636 Ficolin-3 33395 205 71/24 12/7 ↑
B25 P36980 Complement factor H-related protein 2 31543 70 25/8 6/4 ↑
B26 O95455 Apolipoprotein M 21582 49 22/3 7/3 ↑
B27 P02753 Retinol binding protein 4 23337 230 42/15 7/5 ↑
B28 P02753 Retinol binding protein 4 23337 1071 154/74 9/8 ↑
B29 P02656 Apolipoprotein C-III 10846 84 10/4 2/4 ↓
Protein names in italic: proteins found also in the comparison between BPH without inflammation and BPH with inflammation (Table 6).
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nant and benign condition.
Methods
Study population
Ninety patients with clinical suspect of PCa (serum PSA
elevation and/or palpable mass at DRE) and candidates
for TRUS guided biopsy were enrolled. The recruitment
was done at the Department of Urology, University Hos-
pital of Modena and Reggio Emilia. Participants pro-
vided written informed consent and the local research
Ethical Committee (Comitato Etico Provinciale di Modena)
approved the study design.
The median patients age was 67 years (range 57–81).
We excluded subjects with relevant systemic diseases orsignificant clinical events during the 6 months before
the recruitment and patients that received hormonal
treatment or radio-chemotherapy. All patients under-
went a 12 months follow up.
Histological examination and patients’ classification
All enrolled patients underwent to TRUS guided biopsy
with a 16-G needle. A total of 12 samples (6 per side)
were obtained from each biopsy. Each transrectal ultra-
sound performed included an assessment of prostatic
diameter, the volume of the whole prostate, and the
transition zone and capsular and seminal vesicle charac-
teristics, as well as a morphological description of poten-
tial pathological features in the peripheral or transition
zone. Each histological specimen was examined by two
Table 6 Differentially expressed proteins in BPH without inflammation vs BPH with inflammation
Spot n°. Acc. n°. Protein full name Mass (Da) Score N° matchs/signif. matchs N° seq./signif. seq. Expression
change
D1 P00751 Complement factor B 86847 501 196/57 34/15 ↑
D2 P06396 Gelsolin 86043 301 141/37 25/14 ↑
D3 P00734 Prothrombin 71475 168 42/14 12/5 ↑
D4 P02749 Beta-2-glycoprotein 1 39584 39 15/2 5/2 ↑
D5 P02749 Beta-2-glycoprotein 1 39584 41 32/15 7/4 ↑
D6 P02749 Beta-2-glycoprotein 1 39584 331 72/30 13/9 ↑
D7 P02749 Beta-2-glycoprotein 1 39584 204 70/33 13/7 ↑
D8 P02774 Vitamin-D binding protein 54526 1679 283/149 32/28 ↑
D9 P01011 Alpha-1-antichymotrypsin 47792 324 54/24 11/8 ↑
D10 P02765 Alpha-2-HS-glycoprotein 40098 273 96/38 11/9 ↑
D11 P01024 Complement C3 (fragment) 188569 700 210/73 33/16 ↑
D12 P01024 Complement C3 (fragment) 188569 1500 300/126 42/23 ↑
D13 P25311 Zinc-alpha-2-glycoprotein 34465 66 15/6 6/3 ↑
D14 P10909 Clusterin 53031 83 21/4 8/2 ↑
D15 P10909 Clusterin 53031 245 42/14 8/4 ↑
D16 P10909 Clusterin 53031 159 39/14 8/6 ↑
D17 P10909 Clusterin 53031 174 25/11 6/3 ↑
D18 P01024 Complement C3 fragment 188569 834 119/57 16/10 ↑
D19 P02753 Retinol binding protein 4 23337 585 134/64 9/9 ↑
D20 P02656 Apolipoprotein C-III 10846 231 7/7 2/2 ↑
D21 P00738 Haptoglobin 45861 524 102/43 15/10 ↓
D22 P00738 Haptoglobin 45861 348 90/34 17/9 ↓
D23 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 103521 222 30/19 7/6 ↓
D24 P0DJI8 Serum amyloid A-1 protein 13581 269 26/13 10/5 ↓
D25 P0DJI8 Serum amyloid A-1 protein 13581 360 29/16 10/5 ↓
Protein names in italic: proteins found also in the comparison between PCa without inflammation and PCa with inflammation (Table 5).
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PCa and BPH, besides the presence of inflammation.
The histological criterion used to define inflammation was
the presence of pathological infiltration of the prostatic
tissue by inflammatory cells, evaluated by hematoxylin
and eosin stain.
Radical prostatectomy was performed in cases of
histological diagnosis of PCa at biopsy.
Histological examination recognized PCa (31 patients),
BPH (30 patients), high-grade prostatic intraepithelial
neoplasia (HGPIN, 13 patients), prostate adenoma (PA,
5 patients) and inflammation.
BPH was defined a non neoplastic increase of glandu-
lar and/or stromal components of the prostatic glands
clinically characterized by enlargement of the gland,
while PA was defined a prominent nodular proliferation
of crowded benign small to medium-sized glands with
inconspicuous nuclei.
Since the purpose of the present study was to detect
differences in the serum proteomic profiles of PCa andBPH, all cases of HGPIN and PA were excluded. Fur-
thermore, others 11 cases were not analyzed due to
problems occurred during serum processing. Then, the
analysis was performed on a total of 61 cases from the
initial 90 patients enrolled. Clinical data of the patients
analyzed are shown in Table 8.
Tumors were stratified according to the TNM classifi-
cation [35] and Gleason grading system [36]: 25 cases
were organ-confined tumor (pT1-pT2) and 6 cases were
non-organ confined tumor (pT3); 14 cases were gradu-
ated as Gleason score < 7 and 7 cases with Gleason
score ≥ 7.
Serum samples
Before prostatic biopsy, venous blood was collected into
vacutainer serum separation tubes and allowed to clot at
room temperature for 1 hour. Serum was separated by
centrifugation at 2,000 x g for 10 min at 4°C. After the
addition of a protease inhibitor cocktail (Sigma-Aldrich)
to prevent protein enzymatic breakdown or modifications,
Table 7 Proteins differentially expressed in the absence of inflammation in PCa vs BPH
Spot n°. Acc. n°. Protein full name Mass (Da) Score N° matchs/signif. matchs N° seq./signif. seq. Expression
change
A1 P00734 Prothrombin 71475 122 29/11 8/5 ↑
A2 P00734 Prothrombin 71475 31 17/2 6/2 ↑
A3 P0C0L5 Complement C4-B (fragment) 194170 2320 117/90 20/17 ↑
A4 P01024 Complement C3 (fragment) 188569 1531 134/78 54/36 ↑
A5 P01024 Complement C3 (fragment) 188569 209 27/12 15/6 ↑
A6 P00738 Zinc-alpha-2-glycoprotein 45861 1037 95/61 20/17 ↑
A7 P01024 Complement C3 (fragment) 188569 46 9/3 6/3 ↑
A8 P01024 Complement C3 (fragment) 188569 69 24/8 7/5 ↑
A9 P02790 Hemopexin 52385 1160 310/114 30/21 ↓
A10 P01008 Antithrombin-III 53025 542 136/50 26/13 ↓
A11 P36955 Pigment epithelium-derived factor 46454 166 33/15 10/8 ↓
A12 P36955 Pigment epithelium-derived factor 46454 422 61/35 12/10 ↓
A13 P00738 Haptoglobin 45861 437 52/31 8/8 ↓
A14 P00738 Haptoglobin 45861 871 90/52 20/15 ↓
A15 P0DJI8 Serum amyloid A-1 protein 13581 111 17/8 8/2 ↓
A16 P0DJI8 Serum amyloid A-1 protein 13581 244 34/22 9/6 ↓
Protein names in italic: proteins found also in the previous comparison in the presence of inflammation (Tables 5 and 6).
Protein names in bold: proteins not previously identified in presence of inflammation.
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at −80°C until use. A quality control sample (QC) was
prepared by pooling an equal amount of serum from
healthy donors. The QC sample was used to assess the re-
producibility of each SELDI-ToF-MS experiment and as
control for each obtained protein profile.
Serum immunodepletion
The presence of highly abundant proteins can interfere
with the resolution and sensitivity of the proteomic tech-
niques used to analyse the serum profiles. For this reason,
serum samples were depleted by immunoaffinity chroma-
tography using a Multiple Affinity Removal SystemTable 8 Clinical data of enrolled patients
PCa (n = 31) BPH (n = 30)
Median age (years) 67 68
PSA (range ng/mL) 0.20 – 25.00 0.80 – 34.36
Gleason score
G < 7 14 /
G≥ 7 17 /
Tumor clinical stage
T1 5 /
T2 20 /
T3 6 /
Inflammation
Absence 10 11
Presence 21 19(MARS) column (4.6 mm ID × 100 mm, Agilent Tech-
nologies Inc., CA, USA) containing antibodies against the
six most abundant serum proteins: albumin, IgG, IgA,
transferrin, haptoglobin and alpha-1-antitrypsin. The de-
pletion is expected to remove about 88-92% of the total
protein content. Removal was performed according to the
recommendations of the manufacturer. Briefly, 200 μL of
diluted sample were injected in a Beckman System Gold
HPLC (Beckman Coulter, Fullerton, CA, USA). The low-
abundance protein fractions eluted were aliquoted and
stored at −20°C until analysis. The QC was also depleted
following the same procedure.
SELDI-ToF-MS analysis
A SELDI-ToF mass spectrometer Series 4000 (Bio-Rad
Laboratories Inc., Hercules, CA, USA) was used to ana-
lyse the depleted serum samples. After some tests, the
H50 (reverse-phase) ProteinChip Array, a surface able to
selectively bind proteins with hydrophobic residues, gave
the best serum profiles in terms of proteins number and
resolution, so was selected for our experiments.
The analysis was performed as described in Monari
et al. [37]. Shortly, depleted serum sample (20 μL) was
mixed with ProteinChip binding buffer (110 μL) contain-
ing 10% acetonitrile (ACN) and 0.1% trifluoroacetic acid
(TFA), and loaded onto pre-equilibrated H50 Pro-
teinChip Array spot surfaces. After incubation, saturated
sinapinic acid solution was applied to each spot and
samples were analyzed with two different reading proto-
cols optimized for low and high MW (laser energy
Bergamini et al. Proteome Science 2014, 12:32 Page 10 of 12
http://www.proteomesci.com/content/12/1/322500 nJ and 5000 nJ, respectively). The protein mass spec-
tra were generated using an average of 901 laser shot, and
the “All-in-one protein standard” (Bio-Rad) was used to
generate a protein standard spectrum for mass accuracy
calibration, for both reading protocols.
ProteinChip Data Manager 3.0 software (Bio-Rad) was
employed for statistical analysis; the spectra were cali-
brated, baseline subtracted, mass aligned and normalized
by total ion current in the range of 2–30 kDa and 30–
100 kDa for low and high MW, respectively. Poor quality
spectra with a normalization factor greater than twice
the median value were excluded. Supervised clustering
was performed using the following settings: 5 times
signal-to-noise (S/N) ratio, 3 times S/N valley depth,
20% min peak threshold in the first pass for peaks iden-
tification, and 2 times S/N ratio on the second pass for
cluster completion.
To asses reproducibility the coefficient of variation (%
CV) of peaks obtained from QC sample replicates were
used. The pooled% CV mean was 19.08% indicating that
no analytical bias was present during the experiment.
After clusters identification, Student t-tests were per-
formed and a p-value ≤ 0.05 was accepted as statistically
significant.
Two-dimensional gel electrophoresis
The immunodepleted serum samples, precisely the low-
abundance protein fractions eluted, were first buffer-
exchanged using 20 mm Tris–HCl, pH 7.4, by 5 kDa MW
cut-off spin concentrators (Agilent Technologies). The
samples were subjected to 3 cycles of buffer addition,
with centrifugation at 7,500 x g at 10°C for 20 min
every time.
Protein concentration was determined by the Bradford
method [38], using the Protein Assay Dye Reagent (Bio-
Rad). Eighty micrograms of proteins were diluted to
300 μL with a rehydration buffer composed of 6 M urea,
2 M thiourea, 4% CHAPS, 25 mM dithiothreitol (DTT),
0.2% ampholytes, and loaded onto 17 cm immobilized
pH-gradient (IPG) strips, pH range 4–7 (Ready Strip™,
Bio-Rad). Proteins were separated in first dimension
through isoelectric focusing at 20°C, by an initial step of
rehydration at 50 V for 12 h, followed by a second step
at 250 V for 15 min, ramping up to 10.000 V for 3 h and
finally focusing to reach 75.000 V-h.
Subsequently, the strips were equilibrated by incuba-
tion for 15 min at room temperature, first with 1% DTT
and then with 2.5% iodoacetamide, both dissolved in
equilibration buffer containing 6 M urea, 2% sodium-
dodecyl-sulphate (SDS), 30% glycerol, 50 mM Tris–HCl
pH 8.8 and trace of bromophenol blue. Second dimen-
sion separation was achieved by SDS-PAGE (SDS-poly-
acrylamide gel electrophoresis), using 8-16% acrylamide
gradient gel and a running buffer composed of 192 mMglycine, 0.1% SDS and 25 mM Tris–HCl, pH 8.3. The
equilibrated strips were embedded into a solution of
0.5% agarose on the top of the gel and electrophoresis
was performed at 80 mA/gel for the first 30 min, then
the voltage increased to 500 V until the dye font reached
the bottom of the gel. After 2-DE, proteins were visual-
ized by a Silver nitrate staining protocol, as previously
reported in detail [39].
Then, the gels were acquired using a GS-800 cali-
brated densitometer (Bio-Rad) and the gel images were
exported to the PDQuest 2-D Image Analysis software,
version 7.3.1. (Bio-Rad). This software compares 2-DE
gel images, identifying differential protein expression by
the detection of increase or decrease protein spot on the
basis of their staining intensities.
In the present study, the differentially expressed pro-
tein spots were excised and “in-gel” trypsin digested, as
previously fully described [39].
Protein identification by LC MS/MS
Obtained peptides were vacuum concentrated and then
were dissolved in 10 μL of Buffer A, composed of 3%
ACN with 0.1% Formic Acid (FA). Digested peptides
(4 μL) were analyzed by the 6520 Accurate-Mass ESI-Q-
ToF coupled with a 1200 Nano HPLC-Chip microfluidic
device (Agilent Technologies). Sample separation was
performed as previously described figure In brief, the
samples were loaded from the autosampler into the Chip
enrichment column (Zorbax C18, 4 mm × 5 μm i.d., Agi-
lent Technologies) by a capillary pump, with a loading
flow of 4 μL/min using Buffer A. Nitrogen was used as
the nebulising gas. A separation column (Zorbax C18,
43 mm × 75 μm i.d., Agilent Technologies) was used for
peptide separation, setting the analytical flow rate at
0.4 μL/min. Elution was obtained with Buffer B (97%
ACN, 0.1% FA). Total run time was 40 min.
Protein-identification peak lists were generated using
Mascot server (Matrix Science, UK. Mascot 2.4). Swis-
sProt protein database (SwissProt 2013_04) was selected,
specifying the following parameters: Homo sapiens tax-
onomy, parent ion tolerance ± 20 ppm, MS/MS error
tolerance ± 0.1 Da, alkylated cysteine as fixed modifica-
tion, oxidized methionine as variable modification, and
two potential missed trypsin cleavages. Proteins were
considered identified with at least 2 unique peptides.
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